What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?

Keong Tatt Foo, Keong Tatt Foo

Abstract

Introduction: Though clinical benign prostatic hyperplasia (BPH) is a common disease worldwide, there is still much confusion in the literature and the many clinical guidelines as to its definition. Often the disease is associated with lower urinary tract symptoms (LUTS) and managed according to only symptoms. This leads to undertreatment in some patients with severe bladder outlet obstruction (BOO) with no symptoms, and overtreatment in patients with LUTS but no clinical BPH.

Definition of a disease: Fundamentally, a disease can be defined as an abnormal structure or function or a condition which may cause harm to the organism.

Definition of clinical bph: Thus, clinical BPH can be defined as prostate adenoma/adenomata, causing a varying degree of BOO, which may eventually cause harm to the patients. With this definition, we are then able to differentiate the disease clinical BPH from the many other less common causes of LUTS, and then treat it according to its severity.

Diagnosing clinical bph: Clinical BPH can be diagnosed with non-invasive ultrasound in the clinic, grading it according to the shape (intravesical prostatic protrusion) and size of the prostate.

Clinical significance: Treatment can then be planned according to the disease severity using our staging system that classifies severity according to the presence or absence of significant obstruction and bothersomeness of symptoms.

Conclusion: This would lead to better individualised and cost-effective management of the disease clinical BPH.

Keywords: Benign prostatic hyperplasia; Definition; Grading; Individualised care; Staging; Transabdominal ultrasound.

Conflict of interest statement

The author declares that he has no conflict of interest.

References

    1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A, Standardisation Sub-Committee of the International Continence Society The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49. doi: 10.1016/S0090-4295(02)02243-4.
    1. Hirayama A, Samma S, Fujimoto K, Yamaguchi A, Akiyama T, Fukui Y. Comparison of parameters to determine the cause of urinary disturbance in men with prostate volume less than 20 milliliters. Int J Urol. 2002;9(10):554–559. doi: 10.1046/j.1442-2042.2002.00524.x.
    1. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO, Gravas S. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–1109. doi: 10.1016/j.eururo.2014.12.038.
    1. Foo KT. Pathophysiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):152–157. doi: 10.1016/j.ajur.2017.06.003.
    1. Luo GC, Foo KT, Kuo T, Tan G. Diagnosis of prostate adenoma and the relationship between the site of prostate adenoma and bladder outlet obstruction. Singap Med J. 2013;54(9):482–486. doi: 10.11622/smedj.2013168.
    1. Foo KT. Solving the benign prostatic hyperplasia puzzle. Asian J Urol. 2016;3(1):6–9. doi: 10.1016/j.ajur.2015.11.003.
    1. Tan YH, Foo KT. Predicting the outcome of trial voiding following acute urinary retention using transabdominal ultrasound. J Urol. 2001;165(6):269.
    1. Foo KT, Lee LS. Re: intravesical prostatic protrusion (IPP) and uroflowmetry in the management of benign prostatic enlargement (BPE) Int J Urol. 2010;17(6):589. doi: 10.1111/j.1442-2042.2010.02533.x.
    1. Zhang KY, Xing JC, Chen BS, Liu CX, Lau HW, Sim HG, Foo KT. Bipolar plasmakinetic transurethral resection of the prostate vs. transurethral enucleation and resection of the prostate: pre- and postoperative comparisons of parameters used in assessing benign prostatic enlargement. Singap Med J. 2011;52(10):747–687514.
    1. Singapore Urological Association Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Guidelines Committee 2015 Singapore urological association clinical guidelines for male lower urinary tract symptoms/benign prostatic hyperplasia. Singapore Med J. 2017;58(8):473–480. doi: 10.11622/smedj.2017082.
    1. Foo KT. Current assessment and proposed staging of patients with benign prostatic hyperplasia. Ann Acad Med Singap. 1995;24(4):648–651.
    1. Wang D, Huang H, Law YM, Foo KT. Relationships between prostatic volume and intravesical prostatic protrusion on transabdominal ultrasound and benign prostatic obstruction in patients with lower urinary tract symptoms. Ann Acad Med Singap. 2015;44(2):60–65.
    1. Wang D, Foo KT. Staging of benign prostate hyperplasia is helpful in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia. Ann Acad Med Singap. 2010;39(10):798–802.
    1. Foo KT. Decision making in the management of benign prostatic enlargement and the role of transabdominal ultrasound. Int J Urol. 2010;17(12):974–979. doi: 10.1111/j.1442-2042.2010.02668.x.
    1. Lim KB, Ho H, Foo KT, Wong MY, Fook-Chong S. Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. Int J Urol. 2006;13(12):1509–1513. doi: 10.1111/j.1442-2042.2006.01611.x.
    1. Kuo TL, Teo JS, Foo KT. The role of intravesical prostatic protrusion in the evaluation and treatment of bladder outlet obstruction (BOO) Neurourol Urodyn. 2016;35(4):535–537. doi: 10.1002/nau.22741.
    1. Mangat R, Ho HSS, Kuo TLC. Non-invasive evaluation of lower urinary tract symptoms (LUTS) in men. Asian J Urol. 2018;5(1):42–47. doi: 10.1016/j.ajur.2017.12.002.
    1. Bright E, Oelke M, Tubaro A, Abrams P. Ultrasound estimated bladder weight and measurement of bladder wall thickness—useful noninvasive methods for assessing the lower urinary tract? J Urol. 2010;184(5):1847–1854. doi: 10.1016/j.juro.2010.06.006.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera